| First character of title | Commenter | Comment Information |
A
|
Date: 07/30/2010
Comment:
"It's not what you don't know that hurts you.
It's what you know that just ain't so."
Dear colleagues, remember that gross negligence
begins where questioning stops. We owe ourselves
uncompromised standards, and we owe
More opens in new window
|
|
Date: 07/29/2010
Comment:
For any new readers of the Provenge Comments page or those just checking again, a few summary thoughts that will hopefully answer any lingering basic questions. Moreover, a list of selected comments on this page, all supportive of Provenge,
More opens in new window
|
|
Title: Doctor
Organization: Memorial Sloan-Kettering Cancer Center
Date: 07/19/2010
Comment:
Dear members of the CMS/NCD review board: As a concerned physician, I want to highlight the career-ending impact Provenge may have for the highly paid chemotherapy oncologists whose cancer patients can now be treated by the more affordable
More opens in new window
|
|
Date: 07/30/2010
Comment:
CHEMO KILLS FASTER, DESTROYS IMMUNE SYSTEM & COSTS MORE!
I find it totally incredible that Provenge is even being reviewed when you consider the cost, length of research and trials conducted, the thorough review by the FDA in
More opens in new window
|
|
Title: Health Policy Researcher and Patient Advocate
Date: 07/19/2010
Comment:
I urge CMS to quickly conclude or withdraw this NCA as it is both wasteful and harmful to patients. As a health researcher and advocate for patients with a specific expertise in scientific and regulatory policy as it relates to oncology, I
More opens in new window
|
|
Date: 07/17/2010
Comment:
Dear members of the CMS NCD review board, As a concerned scientist, physician and citizen, I am writing to alert you to the multiple suppressed but significant faults of the Provenge phase 3 clinical program. In the interest of higher
More opens in new window
|
|
Title: Physician Scientist
Date: 07/30/2010
Comment:
Is it rational or justified to use billion$ taxpayers’ money to cover something whose effectiveness has been highly questioned and whose safety profile shows a 3% treatment death rate? A proper answer to this question relates not only to CMS,
More opens in new window
|
|
Date: 07/25/2010
Comment:
[PHI Redacted]
We have a current member who has done a wonderful job of being his own "medical consultant" and has over the years tried everything. He is still relatively young, still enjoying life after retitement with his
More opens in new window
|
|
Date: 07/11/2010
Comment:
I have posted positively concerning on label use, I would like to give a large yes to off label prescribing, [PHI Redacted]....Thanks, and approve please....John
More opens in new window
|
|
Date: 07/01/2010
Comment:
Most of my family's males have suffered the end
trails of PC, and the ravages of Taxotere, we
need the product for a more meaningful quality of
life towards the end of the process. Thanks, John
More opens in new window
|
|
Title: US Taxpayer
Date: 07/09/2010
Comment:
Moving past the debate on safety, efficacy,
flaws, approvability and liability, there is no
reason why a life-extending intervention (N.B.
*not* life-saving) such as Provenge should cost
the US Treasury and the US taxpayers
More opens in new window
|
|
Title: President
Organization: Renal hypertension Center
Date: 07/03/2010
Comment:
Dear Sir
Metastatic prostate cancer is one of the most devastating
disease . The treatment option is limited and has significant side
effects.
Autologous cellular therapy ( vaccine) has been one the major
breakthroughs in the
More opens in new window
|
|
Date: 07/09/2010
Comment:
As a citizen and taxpayer of the United States, I
urge the CMS to provide payment for the use of
Provenge in all situations requiring treatment of
prostate cancer. The evidence provided by the
phase-3 trials is irrefutable and
More opens in new window
|
|
Date: 07/16/2010
Comment:
Dendreon received FDA approval for Provenge based on the results of years of clinical trials...results which proved the efficacy of the treatment and which were INDISPUTABLE. Why now the confusion being created by the CMS review? Dying men
More opens in new window
|
|
Date: 07/26/2010
Comment:
Medical science has discovered a new treatment for
prostate cancer. This is the first new therapy
available to men with prostate cancer in some 20
years. It is also the first therapy available for
prostate cancer that can offer hope
More opens in new window
|
|
Date: 07/27/2010
Comment:
Please provide full coverage of Provenge for both
on and off label. This is the future of cancer
treatments and needs to be supported fully.
Although, the chemo cartel does not want such
treatments approved, covered and utilized,
More opens in new window
|
|
Date: 07/28/2010
Comment:
Drs. Paserchia & Fitterman, if a private company was responsible
for the premature death of hundreds of cancer patients would you
really want to
More opens in new window
|
|
Date: 07/08/2010
Comment:
I urge you to consider covering Dendreon's Provenge 100%. This new breakthrough treatment for Prostate cancer is desperately needed considering the other alternatives, taxotere (chemotherapy) and death. Provenge has proven well beyond the
More opens in new window
|
|
Date: 07/11/2010
Comment:
Please make Provenge available NOW to men who
suffer from prostate cancer! Their treatment
options are basically Provenge and Taxotere and
Taxotere has horrible side effects while Provenge
has very mild flu like side effects.
More opens in new window
|
|
Organization: Malecare Miami
Date: 07/26/2010
Comment:
[PHI Redacted] They've been reading and looking forward to the promise of Provenge and other, similar treatments. I don't understand this CMS or what the problem is with Medicare paying for this. I only know that these guys
More opens in new window
|
|
Date: 07/19/2010
Comment:
I urge you to approve Medicare payments for
Provenge. I fail to understand how Taxotere is
aproved for payment without approving Provenge.
I fear this is the financial equivalent of the
death panels we all heard about during
More opens in new window
|
|
Title: CO-DIVISION CHIEF, GENITOURINARY ONCOLOGY
Organization: HACKENSACK UNIVERSITY MEDICAL CENTER
Date: 07/29/2010
Comment:
WAS INVOLVED WITH PROVENGE''S CLINICAL TRIALS IN
THE PAST AND STILL HAVE SEVERAL PATIENTS
CHEMO-NAIVE, WITH EXCELLENT QOL.
EFFECTIVE THERAPY, WELL TOLERATED AND STRONGLY
RECOMMENDED FOR THE APPROPRIATE
More opens in new window
|
|
Title: Citizen of the United States of America
Organization: humanity
Date: 07/22/2010
Comment:
I will keep this as brief as possible. Chemo has seen it's last days. Yet, big Pharma and the new healthcare bill would like to keep it alive. Provenge is the future and nothing will keep that from happening. Being nearly seventy, I know
More opens in new window
|
|
Title: Director, Prostate and genitourinary cancer progra
Organization: Comprehensive cancer center of the desert
Date: 07/30/2010
Comment:
I am a private practitioner of Medical Oncology
specializing in management of Prostate cancer
with 10 years experience. Patients come to us
with a lot of hope of prolongation of their lives
without significantly altering theri
More opens in new window
|
|
Date: 07/30/2010
Comment:
This is for you [PHI Redacted].
With three extra months you would have seen me graduate college. The first in our family.
With four extra months I could have told you stories about my backpacking trip through
More opens in new window
|
